

# Joan Trujols

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7370561/publications.pdf>

Version: 2024-02-01

85  
papers

1,390  
citations

361413

20  
h-index

377865

34  
g-index

90  
all docs

90  
docs citations

90  
times ranked

1687  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interim opioid agonist treatment for opioid addiction: a systematic review. Harm Reduction Journal, 2022, 19, 7.	3.2	4
2	Patient-reported outcome measures ( <scp>PROMs</scp> ) to guide clinical care: recommendations and challenges. Medical Journal of Australia, 2022, 217, 110-110.	1.7	2
3	Factors associated with the absence of cocaine craving in treatment-seeking individuals during inpatient cocaine detoxification. American Journal of Drug and Alcohol Abuse, 2021, 47, 127-138.	2.1	2
4	Impulsivity, Emotion Regulation, Cognitive Distortions and Attentional Bias in a Spanish Sample of Gambling Disorder Patients: Comparison between Online and Land-Based Gambling. International Journal of Environmental Research and Public Health, 2021, 18, 4869.	2.6	3
5	Por una priorizaci3n de las personas con trastornos adictivos en la vacunaci3n frente a la COVID-19. Revista De Psicología De La Salud, 2021, 33, 285.	0.5	1
6	Unhappy While Depressed: Examining the Dimensionality, Reliability and Validity of the Subjective Happiness Scale in a Spanish Sample of Patients with Depressive Disorders. International Journal of Environmental Research and Public Health, 2021, 18, 10964.	2.6	1
7	Individualized and Standardized Outcome Measures: Further Arguments in Favor of Cohabitation. Administration and Policy in Mental Health and Mental Health Services Research, 2020, 47, 339-343.	2.1	3
8	Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: Should this practice be incorporated into routine clinical care?. Journal of Substance Abuse Treatment, 2020, 119, 108154.	2.8	34
9	Mindfulness-Based Interventions for Addiction. Mindfulness, 2020, 11, 2034-2034.	2.8	1
10	Towards a common metric for assessing heroin-dependent patient satisfaction with medications: Testing methadone and buprenorphine-naloxone. Drug and Alcohol Dependence, 2020, 212, 108010.	3.2	1
11	Effectiveness of Integrative Laughter Therapy to Reduce Anxiety, Improve Self-Esteem and Increase Happiness: A Naturalistic Study at a Day Hospital for Addictive Disorders. International Journal of Environmental Research and Public Health, 2019, 16, 4194.	2.6	9
12	Differences in Emotion Regulation Considering Gender, Age, and Gambling Preferences in a Sample of Gambling Disorder Patients. Frontiers in Psychiatry, 2019, 10, 625.	2.6	16
13	Testing the efficacy of INtegral Cognitive REMediation (INCREM) in major depressive disorder: study protocol for a randomized clinical trial. BMC Psychiatry, 2019, 19, 135.	2.6	6
14	Quality of life and well-being from the perspective of patients on opioid agonist maintenance treatment: study protocol for a systematic review of qualitative research and a scoping review of measures. Systematic Reviews, 2019, 8, 299.	5.3	1
15	Level of satisfaction of critical care patients regarding the nursing care received: Correlation with sociodemographic and clinical variables. Australian Critical Care, 2019, 32, 486-493.	1.3	12
16	Opioid agonist dosage adequacy from clinical and patient perspectives: further considerations. Cmaj, 2019, 191, E1084-E1084.	2.0	3
17	Estudio psicom3trico de la Escala de valoraci3n de los Niveles de Atenci3n Requerida para personas con Trastorno Mental Grave (ENAR-TMG). Revista De Psiquiatr3a Y Salud Mental, 2018, 11, 156-168.	1.8	4
18	Nursing Intensive3Care Satisfaction Scale [ <scp>NICSS</scp>]: Development and validation of a patient3centred instrument. Journal of Advanced Nursing, 2018, 74, 1423-1435.	3.3	12

#	ARTICLE	IF	CITATIONS
19	Cognitive predictors of illness course at 12 months after first-episode of depression. <i>European Neuropsychopharmacology</i> , 2018, 28, 529-537.	0.7	27
20	A cluster-analytic profiling of heroin-dependent patients based on level, clinical adequacy, and patient-desired adjustment of buprenorphine dosage during buprenorphine-naloxone maintenance treatment in sixteen Spanish centers. <i>Drug and Alcohol Dependence</i> , 2018, 187, 278-284.	3.2	6
21	Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment. <i>Drug and Alcohol Dependence</i> , 2018, 183, 127-133.	3.2	12
22	Heroin-dependent patient satisfaction with methadone as a medication influences satisfaction with basic interventions delivered by staff to implement methadone maintenance treatment. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1203-1211.	1.8	8
23	Looking into the effect of multi-item symptom domains on psychometric characteristics of the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16). <i>Psychiatry Research</i> , 2018, 267, 126-130.	3.3	4
24	Digging into the construct of fibrofog: Psychometric properties of the Spanish version of the Multidimensional Inventory of Subjective Cognitive Impairment in patients with fibromyalgia. <i>Journal of Applied Biobehavioral Research</i> , 2018, 23, e12134.	2.0	8
25	Development and validation of the scale to assess satisfaction with medications for addiction treatment “Buprenorphine-naloxone for heroin addiction (SASMAT-BUNHER). <i>International Journal of Drug Policy</i> , 2018, 58, 126-134.	3.3	5
26	Mindfulness-Based Interventions for the Treatment of Substance and Behavioral Addictions: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2018, 9, 95.	2.6	130
27	Psychometric study of the Required Care Levels for People with Severe Mental Disorder Assessment Scale (ENAR-TMG). <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2018, 11, 156-168.	0.3	0
28	La adicción como enfermedad: ¿mitigando o alimentando el estigma?. <i>Revista De Psicología De La Salud</i> , 2018, 30, 225.	0.5	1
29	Validation of a Spanish version of the Schizotypal Personality Questionnaire (SPQ): Psychometric characteristics and underlying factor structure derived from a healthy university student sample. <i>Actas Espanolas De Psiquiatria</i> , 2018, 46, 159-73.	0.1	2
30	Patient perception of methadone dose adequacy in methadone maintenance treatment: The role of perceived participation in dosage decisions. <i>Patient Education and Counseling</i> , 2017, 100, 981-986.	2.2	18
31	Satisfaction With Methadone and Opioid Receptor Genes Polymorphisms in Treatment-Refractory Heroin-Dependent Patients. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 378-380.	1.4	2
32	Aproximacions a la perspectiva de la persona en tractament de manteniment amb metadona: Reflexions a propòsit de 10 anys de recerca / Approaches to the perspective of the individual receiving methadone maintenance treatment: Reflections on 10 years of research. <i>Aloma</i> , 2017, 35, 39-50.	0.6	0
33	NATURALISTIC COURSE OF MAJOR DEPRESSIVE DISORDER PREDICTED BY CLINICAL AND STRUCTURAL NEUROIMAGING DATA: A 5-YEAR FOLLOW-UP. <i>Depression and Anxiety</i> , 2016, 33, 1055-1064.	4.1	19
34	Satisfaction With Methadone Among Heroin-Dependent Patients With Current Substance Use Disorders During Methadone Maintenance Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 157-162.	1.4	7
35	Deep Brain Stimulation for Addiction Treatment: Further Considerations on Scientific and Ethical Issues. <i>Brain Stimulation</i> , 2016, 9, 788-789.	1.6	2
36	Towards a genuinely user-centred evaluation of harm reduction and drug treatment programmes: A further proposal. <i>International Journal of Drug Policy</i> , 2015, 26, 1285-1287.	3.3	11

#	ARTICLE	IF	CITATIONS
37	Improving systematic reviews on psychometric properties of measurement instruments: A letter to the Editor commenting on Reilly et al.'s (2015) review of the psychometric literature on QIDS. Journal of Psychiatric Research, 2015, 62, 136-137.	3.1	0
38	The brain disease model of addiction: challenging or reinforcing stigma?. Lancet Psychiatry, 2015, 2, 292.	7.4	21
39	Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study. BMC Infectious Diseases, 2015, 15, 355.	2.9	4
40	Personality disorders among Spanish prisoners starting hepatitis C treatment: Prevalence and associated factors. Psychiatry Research, 2015, 230, 749-756.	3.3	10
41	The Spanish version of the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16): A psychometric analysis in a clinical sample. Journal of Affective Disorders, 2014, 169, 189-196.	4.1	13
42	A critical analysis of user satisfaction surveys in addiction services: opioid maintenance treatment as a representative case study. Patient Preference and Adherence, 2014, 8, 107.	1.8	46
43	Propiedades psicométricas de la versión española de la Philadelphia Mindfulness Scale. Revista De Psiquiatría Y Salud Mental, 2014, 7, 157-165.	1.8	18
44	Pharmacological and clinical dilemmas of prescribing in comorbid adult attention-deficit/hyperactivity disorder and addiction. British Journal of Clinical Pharmacology, 2014, 77, 337-356.	2.4	24
45	Development and validation of the scale to assess satisfaction with medications for addiction treatment-methadone for heroin addiction (SASMAT-METHER). Drug and Alcohol Dependence, 2014, 142, 79-85.	3.2	11
46	Psychometric properties of the Spanish version of the Cocaine Selective Severity Assessment to evaluate cocaine withdrawal in treatment-seeking individuals. Journal of Substance Abuse Treatment, 2014, 47, 189-196.	2.8	2
47	Validation of the Spanish version of the borderline symptom list, short form (BSL-23). BMC Psychiatry, 2013, 13, 139.	2.6	49
48	Patient-reported outcome measures: Are they patient-generated, patient-centred or patient-valued?. Journal of Mental Health, 2013, 22, 555-562.	1.9	83
49	A psychometric analysis of the Clinically Useful Depression Outcome Scale (CUDOS) in Spanish patients. Journal of Affective Disorders, 2013, 151, 920-923.	4.1	8
50	Trends in the average prescribed dose of methadone: More than a proxy for the evolution of severity of opioid dependence. Journal of Obstetrics and Gynaecology, 2013, 33, 430-430.	0.9	0
51	Satisfaction with Methadone Treatment Among Prison Inmates. Criminal Justice and Behavior, 2013, 40, 1163-1177.	1.8	2
52	Toward a Genuinely Patient-Centered Metric of Depression Recovery. JAMA Psychiatry, 2013, 70, 1375.	11.0	4
53	Not all PROMs reflect patients' perspectives. BMJ, 2013, 346, f1552-f1552.	6.0	5
54	Efectividad del ejercicio físico como intervención coadyuvante en las adicciones: una revisión. Revista De Psicología De La Salud, 2013, 25, 71.	0.5	6

#	ARTICLE	IF	CITATIONS
55	Satisfaction With Methadone as a Medication. Journal of Clinical Psychopharmacology, 2012, 32, 69-74.	1.4	17
56	Feasibility of Double-Blind Clinical Trials with Oral Diacetylmorphine: A Randomized Controlled Phase II Study in an Inpatient Setting. European Addiction Research, 2012, 18, 279-287.	2.4	7
57	Encuesta sobre la satisfacción de los pacientes dependientes de heroína de la Comunidad de Valencia con los centros de tratamiento con metadona. Trastornos Adictivos, 2012, 14, 66-72.	0.1	0
58	Patient satisfaction with methadone maintenance treatment: The relevance of participation in treatment and social functioning. Drug and Alcohol Dependence, 2012, 123, 41-47.	3.2	40
59	Features and prevalence of patients with probable adult attention deficit hyperactivity disorder who request treatment for cocaine use disorders. Psychiatry Research, 2011, 185, 205-210.	3.3	48
60	Drug-dependent inpatients reporting continuous absence of spontaneous drug craving for the main substance throughout detoxification treatment. Drug and Alcohol Review, 2011, 30, 403-410.	2.1	13
61	Patient and clinician's ratings of improvement in methadone-maintained patients: Differing perspectives?. Harm Reduction Journal, 2011, 8, 23.	3.2	18
62	Methadone Maintenance Treatment. Journal of Clinical Psychopharmacology, 2010, 30, 95-96.	1.4	18
63	Personality Traits of Cocaine-Dependent Patients Associated with Cocaine-Positive Baseline Urine at Hospitalization. American Journal of Drug and Alcohol Abuse, 2010, 36, 52-56.	2.1	7
64	Infección por VIH y usuarios de drogas por vía parenteral: Urgencia de la revitalización de los programas de reducción de daños. Revista De Psicología De La Salud, 2010, 22, 135.	0.5	3
65	Political challenges in randomized controlled trials of heroin-assisted treatment for severe heroin addiction: a Spanish experience. Clinical Trials, 2009, 6, 658-659.	1.6	3
66	A typology of heroin-dependent patients based on their history of self-injurious behaviours. Psychiatry Research, 2009, 167, 169-177.	3.3	2
67	Stages of change in dialectical behaviour therapy for borderline personality disorder. British Journal of Clinical Psychology, 2008, 47, 417-426.	3.5	32
68	Multi-episode survival analysis: An application modelling readmission rates of heroin dependents at an inpatient detoxification unit. Addictive Behaviors, 2007, 32, 2391-2397.	3.0	9
69	Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug and Alcohol Dependence, 2007, 89, 190-194.	3.2	43
70	Impaired Response Inhibition Scale for Alcoholism (IRISA): Development and Psychometric Properties of a New Scale for Abstinence-Oriented Treatment of Alcoholism. Alcoholism: Clinical and Experimental Research, 2007, 31, 269-275.	2.4	5
71	Allelic and genotypic associations of DRD2 TaqI A polymorphism with heroin dependence in Spanish subjects: a case control study. Behavioral and Brain Functions, 2007, 3, 25.	3.3	37
72	Contextualizing Methadone-Related Deaths: Failure to Contextualize May Be Considered a Weapon Against Public Health. Therapeutic Drug Monitoring, 2006, 28, 712-713.	2.0	1

#	ARTICLE	IF	CITATIONS
73	Patient perspectives on methadone maintenance treatment in the Valencia Region: Dose adjustment, participation in dosage regulation, and satisfaction with treatment. Drug and Alcohol Dependence, 2005, 79, 405-412.	3.2	31
74	A satisfaction survey of opioid-dependent clients at methadone treatment centres in Spain. Drug and Alcohol Dependence, 2004, 73, 307-313.	3.2	34
75	Morbimortalidad relacionada con el uso de metadona: necesidad de su contextualización. Medicina Clínica, 2004, 122, 116-117.	0.6	0
76	Development and psychometric properties of the Verona Service Satisfaction Scale for methadone-treated opioid-dependent patients (VSSS-MT). Drug and Alcohol Dependence, 2002, 68, 209-214.	3.2	35
77	A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Alcohol-Dependence Disorder: Results from a Multicenter Clinical Trial. Alcoholism: Clinical and Experimental Research, 2002, 26, 1381-1387.	2.4	100
78	The apomorphine test: a biological marker for heroin dependence disorder?. Addiction Biology, 2002, 7, 421-426.	2.6	5
79	A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Alcohol-Dependence Disorder: Results from a Multicenter Clinical Trial. Alcoholism: Clinical and Experimental Research, 2002, 26, 1381-1387.	2.4	2
80	A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcoholism: Clinical and Experimental Research, 2002, 26, 1381-7.	2.4	54
81	Methadone tapering plus amantadine to detoxify heroin-dependent inpatients with or without an active cocaine use disorder: two randomised controlled trials. Drug and Alcohol Dependence, 2001, 63, 187-195.	3.2	23
82	A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. Drug and Alcohol Dependence, 2000, 59, 223-233.	3.2	37
83	Cocaine Use Immediately Prior to Entry in an Inpatient Heroin Detoxification Unit as a Predictor of Discharges Against Medical Advice. American Journal of Drug and Alcohol Abuse, 1997, 23, 267-279.	2.1	56
84	Processes of change assessment in heroin addicts following the Prochaska and DiClemente transtheoretical model. Drug and Alcohol Dependence, 1997, 47, 31-37.	3.2	10
85	The apomorphine test in heroin addicts. Addiction, 1995, 90, 831-835.	3.3	11